Eyepoint Pharmaceuticals (EYPT) Stock Rating Lowered by ValuEngine

Eyepoint Pharmaceuticals (NASDAQ:EYPT) was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating in a research note issued on Monday, February 4th.

Several other equities research analysts also recently commented on EYPT. Zacks Investment Research upgraded Eyepoint Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, November 13th. B. Riley lifted their price objective on Eyepoint Pharmaceuticals from $5.00 to $6.00 and gave the stock a “buy” rating in a report on Tuesday, October 16th. Finally, HC Wainwright set a $5.00 price objective on Eyepoint Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, January 4th.

Shares of EYPT traded up $0.03 during trading hours on Monday, hitting $2.63. The company had a trading volume of 174,894 shares, compared to its average volume of 334,579. Eyepoint Pharmaceuticals has a 52-week low of $1.05 and a 52-week high of $3.94. The firm has a market cap of $249.48 million, a PE ratio of -4.53 and a beta of 1.87. The company has a debt-to-equity ratio of 0.37, a current ratio of 2.57 and a quick ratio of 2.57.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in EYPT. Renaissance Technologies LLC bought a new stake in Eyepoint Pharmaceuticals in the 2nd quarter worth about $2,339,000. BlackRock Inc. grew its stake in shares of Eyepoint Pharmaceuticals by 712.5% during the 4th quarter. BlackRock Inc. now owns 1,232,335 shares of the company’s stock valued at $2,329,000 after purchasing an additional 1,080,662 shares during the period. Essex Investment Management Co. LLC grew its stake in shares of Eyepoint Pharmaceuticals by 322.4% during the 4th quarter. Essex Investment Management Co. LLC now owns 568,141 shares of the company’s stock valued at $1,074,000 after purchasing an additional 433,632 shares during the period. Barclays PLC bought a new stake in shares of Eyepoint Pharmaceuticals during the 4th quarter valued at about $474,000. Finally, EAM Investors LLC bought a new stake in shares of Eyepoint Pharmaceuticals during the 3rd quarter valued at about $661,000. Institutional investors own 53.63% of the company’s stock.

About Eyepoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc, a specialty biopharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases. The company's lead product is ILUVIEN for the treatment of diabetic macular edema; and product candidate is YUTIQ, a non-erodible fluocinolone acetonide insert for the treatment of non-infectious posterior uveitis that is in the Phase III clinical trials.

Further Reading: What does RSI mean?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Eyepoint Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyepoint Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply